Impax Pharmaceuticals Reports Positive Achievements on its Two Leading Brand Product Candidates IPX066 and IPX056

Monday April 20, 2009, 8:47 am EDT

http://finance.yahoo.com/news/Impax-...0121.html?.v=1

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ:IPXL - News) today announced it has commenced a Phase III trial of IPX066 in Parkinson’s Disease (PD) patients based on encouraging interim data collected from the Phase II study in PD patients. It also clarified the U.S. Food and Drug Administration (FDA) requirement for pediatric studies of its investigational medication IPX056.



A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
http://clinicaltrials.gov/ct2/show/NCT00869791

This study is currently recruiting participants.
Verified by IMPAX Laboratories, Inc., March 2009
First Received: March 24, 2009 Last Updated: March 25, 2009

Purpose

This study compares the pharmacokinetics and effectiveness of IPX066 to standard cabridopa-levodopa

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacokinetics/Dynamics Study
Official Title: A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Locations

United States, Michigan
IMPAX Laboratories site Recruiting
Not specified, Michigan, United States, 99999
Contact: Barbara Pruitt 510-404-4138
Principal Investigator: IMPAX Investigator, MD